MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study-Reference-Cited by-同舟云学术

MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study

Published:2020-12 Issue:12 Volume:13 Page:100868
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Liu Xue-wen,Chen Xin-ru,Rong Yu-ming,Lyu Ning,Xu Chun-wei,Wang Fang,Sun Wen-yong,Fang San-gao,Yuan Jing-ping,Wang Hui-juan,Wang Wen-xian,Huang Wen-bin,Xu Jian-ping,Yue Zhen-ying,Chen Li-kun

Funder

National Natural Science Foundation of China

Natural Science Foundation of Hunan Province

Foundation of Hunan Health Committee Research Plan

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference39 articles.

1. Sarcomatoid lung cancer (spindle/giant cells): an aggressive disease?;Venissac;J. Thorac. Cardiovasc. Surg.,2007

2. Outcomes of sarcomatoid carcinoma of the lung: a Surveillance, Epidemiology, and End Results Database analysis;Yendamuri;Surgery,2012

3. Biphasic sarcomatoid carcinoma of the lung: report of 5 cases and review of the literature;Terzi;European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,1997

4. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification;Travis;Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer,2015

5. Palliative chemotherapy for pulmonary pleomorphic carcinoma;Bae;Lung cancer (Amsterdam, Netherlands),2007

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An advanced pulmonary sarcomatoid carcinoma patient harboring a BRAFV600E mutation responds to dabrafenib and trametinib: a case report and literature review;Frontiers in Oncology;2023-07-21

2. Clinicopathological characteristics of Non-Small Cell Lung Cancer (NSCLC) patients with c-MET exon 14 skipping mutation, MET overexpression and amplification;BMC Pulmonary Medicine;2023-07-03

3. Targeted therapy for rare lung cancers: Status, challenges, and prospects;Molecular Therapy;2023-07

4. Molecular characterization ofMETfusions from a large real‐world Chinese population: A multicenter study;Cancer Medicine;2023-06-16

5. Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: A single-center real-world study;Frontiers in Oncology;2023-03-09